Crossmark

Correction to: Cabozantinib as first-line treatment in advanced renal cell carcinoma: a profile of its use

Crossref DOI link: https://doi.org/10.1007/s40267-018-00596-3

Published Online: 2019-01-04

Published Print: 2019-02

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Lyseng-Williamson, Katherine A.
License Information

Text and Data Mining valid from 2019-01-04
More Information

Article History

First Online: 4 January 2019

Change Date: 21 February 2019

Change Type: Correction

Change Details: Paragraph 1, Sentences 1 and 2: the following text, which previously read: